RocaJunyent has advised the URV spin-off company Renalyse, also known as CreatSens Health, in the €1 million financing round led by the Mind the Gap II fund together with Genesis Ventures, and with the participation of the Eurostars program.
This economic injection will allow the company to industrialize and certify its diagnostic and monitoring device for chronic kidney disease.
The funding received through this operation will allow Renalyse to certify its in vitro diagnostic product and reach the market in 2026. This device will be able to remotely measure three key parameters for patients with chronic kidney disease, more than 90,000,000 in the European Union alone.
The RocaJunyent team was formed by Fede Segura Wallin (partner) and Sergio Giménez Beltrán (associate). Both are part of the M&A and corporate department.